AVITA Medical, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report4 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+63.58%
vs ±20.8% implied · ×3.06
shaded = implied · ▲▼ = realized
SentenceRegenity manufactures and supplies Cohealyx , an AVITA Medical-branded, FDA-cleared, collagen-based dermal matrix.
RCEL 10-Kaccession 0001193125-26-049031
SentenceIn July 2024, we entered into an exclusive multi-year development and distribution agreement with Collagen Matrix, LLC d/b/a as Regenity Biosciences ("Regenity"), granting us exclusive rights to market, sell, and distribute Cohealyx, an AVITA-medical branded collagen-based dermal matrix in the U.S., with potential expansion into the European Union ("E.U."), Australia, and Japan.
RCEL 10-Kaccession 0001193125-26-049031
SentenceIn addition, in the United States, we hold the rights to manufacture and exclusively market, sell, and distribute PermeaDerm ® , a biosynthetic wound matrix, under the terms of exclusive multi-year distribution and contract manufacturing agreements with Stedical Scientific, Inc. ("Stedical").
RCEL 10-Kaccession 0001193125-26-049031
SentenceIn January 2024, we entered into an exclusive multi-year distribution agreement with Stedical Scientific, Inc. ("Stedical") to market, sell, and distribute PermeaDerm, a biosynthetic wound matrix in the United States ("U.S.").
RCEL 10-Kaccession 0001193125-26-049031
AVITA Medical has 3 disclosed suppliers and 2 disclosed customers in SEC filings.
Largest filed tie
—
AVITA Medical, Inc.
15.63
Expected move
Inputs8Q avg ±20.1%·×0.94·fair
straddle ±19.7%
spot 15.65exp Nov 20ATM strike 15ATM straddle 3.62IV 123%